Sign in
Taking peoplePhase 3

Testing denecimig for acquired haemophilia A in adults

Tests whether denecimig is safe and works for adults with acquired haemophilia A.

Key facts

Who runs it
Novo Nordisk A/S
Where
Parktown, Johannesburg, South AfricaSee the siteAlso in 17 other countries, 82 sites
Trial code
Registry title
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
Status
Recruiting
Phase
Phase 3
People taking part
84 people, planned
Started
16 Oct 2026
Expected to end
23 Mar 2029
Type of study
Interventional
Treatments tested
  • Denecimig
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults newly diagnosed with acquired haemophilia A who have had a bleed that needed treatment.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Newly diagnosed acquired haemophilia A (AHA), confirmed at screening (FVIII activity <50% and FVIII inhibitors >0.6 Bethesda units), with a bleed that needed treatment.
Earlier treatment
No immune-suppressing or immune-changing drugs for AHA before screening, except up to 2 days of prednisolone (or equivalent) at 100 mg per day or less. Immune-suppressing treatment for other conditions is allowed if started at least 6 months before screening and kept stable.
Biomarker or test result
FVIII activity below 50% and FVIII inhibitors above 0.6 Bethesda units (BU), confirmed at screening.

Main reasons for not taking part

  • Pregnant, breast-feeding or planning pregnancy, or able to become pregnant and not using highly effective contraception
  • Past or current blood clot disease, or risk of it (except an earlier catheter-related clot with no current anti-clot treatment)
  • Life expectancy under 3 months
  • Immune-suppressing treatment for AHA before screening (beyond the short prednisolone allowance)

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
  • Male or female participants (sex assigned at birth, inclusive of all gender identities) newly diagnosed with acquired haemophilia A (AHA) prior to signing the informed consent form, with AHA diagnosis (FVIII activity lesser than (<) 50 percentage (%) and FVIII inhibitors greater than (>) 0.6 Bethesda units [BU]) confirmed at screening
  • Treatment-requiring bleed(s) due to AHA from diagnosis and until screening
  • The participant is capable of following study procedures and able to seek medical attention when needed

Who cannot take part

  • Previous or current thromboembolic disease or eventsa (with the exception of previous catheter associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or risk of thromboembolic disease
  • Therapy with immunosuppressive or immune modulating drugs for treatment of AHA (other than less than or equal to (≤) 2 days of prednisolone (or equivalent) for AHA at a dose ≤100 mg per day) prior to screening
  • Immunosuppressive therapy (IST) initiated prior to AHA diagnosis for other medical conditions (e.g., other autoimmune disorders) is permitted, provided it was initiated greater than or equal to (≥) 6 months prior to screening, has been maintained at a stable dose and regimen since initiation, and is expected to remain at a stable dose and regimen at least during the main treatment period (Weeks 0-12)
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate and highly effective contraceptive method
  • Life expectancy <3 months at the time of screening, as evaluated by the investigator

Where in South Africa

Also in 17 other countries, 82 sites

  • Charlotte Maxeke Johannesburg Academic HospitalParktown, Johannesburg, South AfricaContact: Novo NordiskNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to find out if denecimig is safe and effective for treating people who have acquired haemophilia A. Participants will be in this study for up to around 1 year and 5 months (73 week).

The group in the trial

  • DenecimigTreatment being tested

    Denecimig will be administered subcutaneously.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Multinational, Open-label Study to Investigate Efficacy and Safety of Denecimig (Mim8) in Adults With Acquired Haemophilia A
Plain-language title
Testing denecimig for acquired haemophilia A in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 October 2026